| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8187632 | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics |
Jun, 2021
(2 years ago) | |
| US7709022 | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
Jun, 2021
(2 years ago) | |
|
US8187632 (Pediatric) | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics |
Dec, 2021
(2 years ago) | |
|
US7709022 (Pediatric) | BAYER HLTHCARE | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
Dec, 2021
(2 years ago) | |
Cipro Xr is owned by Bayer Hlthcare.
Cipro Xr contains Ciprofloxacin; Ciprofloxacin Hydrochloride.
Cipro Xr has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Cipro Xr are:
- US8187632
- US7709022
- US8187632*PED
- US7709022*PED
Cipro Xr was authorised for market use on 13 December, 2002.
Cipro Xr is available in tablet, extended release;oral dosage forms.
The generics of Cipro Xr are possible to be released after 23 December, 2021.
Drugs and Companies using CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2002
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
CIPRO XR family patents
